Drug Profile
Pyrotinib - Jiangsu Hengrui Medicine
Alternative Names: BLTN; Irene; Pyrotinib maleate; Pyrroltinib maleate; SHR 1258Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Developer Chinese Academy of Medical Sciences; Fudan University; Jiangsu Hengrui Medicine Co.; Peking Union Medical College Hospital; Shanghai Changzheng Hospital; Sun Yat-Sen University; Tongji University
- Class Antineoplastics; Pyridines; Pyrrolidines; Quinolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 positive breast cancer
- Phase III Non-small cell lung cancer
- No development reported Colorectal cancer; Gastric cancer; Urogenital cancer
Most Recent Events
- 05 Dec 2023 Efficacy and adverse events data from the phase-II clinical trial in HER2-positive-breast-cancer presented at 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 20 Oct 2023 Efficacy data from a phase II PICTURE trial in HER2 positive breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 28 Sep 2023 No recent reports of development identified for phase-0 development in Urogenital-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China